USPTO serial 87349251
XCOPRI
Reviewed by CopyMark Law Group
- Filing date
- Status date
- Registration date
- Mar 20, 2018
- Examiner
- LEASER, ANDREW C
- Law office
- Historical data usage
What this means
Status 702 means the registration is active, Section 8 was accepted, and a Section 15 declaration of incontestability was also accepted. Incontestability strengthens your rights by limiting certain challenges after five years of continuous use. Continue use in commerce and plan for the 10-year Section 8 and 9 renewal.
Need help with XCOPRI?
If you own this trademark, we can monitor new filings and help with USPTO deadlines. If you do not, we can file a new U.S. application.
Current trademark owner
Monitor this mark, or talk with CopyMark about this registration.
Not the owner?
File a new U.S. trademark application, or speak with our attorneys.
Owner
SK Biopharmaceuticals Co., Ltd.
Gyeonggi-do, KR
SK Biopharmaceuticals Co., Ltd.
Seongnam-si, KR
SK Biopharmaceuticals Co., Ltd.
Seongnam-si, KR
Attorney of record
The USPTO lists this attorney as the applicant's representative for correspondence on this application.
Hun Joon Kim
Hun Joon Kim LEX IP Meister, PLLC.5160 Parkstone Drive, Suite 140Chantilly, VA 20151United StatesGoods and services
| Class | Description | Status | First use |
|---|---|---|---|
| 005 | Pharmaceutical [ and veterinary ] preparations for treatment of central nervous system diseases [ , cancer and metabolic diseases ] ; [ sanitary preparations for medical use; ] biological preparations for medical purposes, namely, for the treatment of central nervous system diseases [ , cancer and metabolic diseases ] ; biochemical preparations for medical purposes, namely, for the treatment of central nervous system diseases [ , cancer and metabolic diseases ] ; chemical preparations for pharmaceutical purposes, namely, for the treatment of central nervous system diseases [ , cancer and metabolic diseases ] ; medical preparation of trace elements for human [ and animal ] use, namely, for the treatment of central nervous system diseases [ , cancer and metabolic diseases ] ; [ ferments for pharmaceutical purposes; ] biotechnological preparations for medical purposes, namely, for the treatment of central nervous system diseases [ , cancer and metabolic diseases ] ; [ blood solvent; ] chemical preparations for medicinal purposes, namely, for the treatment of central nervous system diseases [ , cancer and metabolic diseases ] ; chemical preparations for medical [ or veterinary ] purposes, namely, for the treatment of central nervous system diseases [ , cancer and metabolic diseases; chemical preparations for sanitary use; pharmaceutical preparations for immunity adjustment; vitamin preparations; vaccines; dietary supplements; ] therapeutic drugs and agents for the treatment of central nervous system diseases [ , cancer and metabolic diseases ] ; chemico-pharmaceutical preparations for the treatment of central nervous system diseases [ , cancer and metabolic diseases; bacteriological preparations for medical and veterinary use ] | ACTIVE | — |
Related trademarks
CopyMark links this record to cited §2(d) serials, the owner's other marks, Nice classes, similar mark names, and recently changed USPTO applications.
- Other trademarks owned by SK Biopharmaceuticals Co., Ltd.
- Other trademarks owned by SK Biopharmaceuticals Co., Ltd.
- Other trademarks owned by SK Biopharmaceuticals Co., Ltd.
- Other trademarks in Class 005
- Similar marks named XCOPRI
- Recently changed USPTO trademarks
- Recently filed trademarks
- Browse all trademark records
Prosecution history
| Date | Code | Event | What it means |
|---|---|---|---|
| Nov 27, 2024 | TCCA | TEAS CHANGE OF CORRESPONDENCE RECEIVED | — |
| Nov 27, 2024 | ECDR | TEAS CHANGE OF DOMESTIC REPRESENTATIVES ADDRESS | — |
| Nov 27, 2024 | EWOR | TEAS WITHDRAWAL AS DOMESTIC REPRESENTATIVE RECEIVED | — |
| Nov 27, 2024 | ARAA | ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED | This event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action. |
| Nov 27, 2024 | REAP | TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED | — |
| Nov 8, 2024 | NA85 | NOTICE OF ACCEPTANCE OF SEC. 8 & 15 - E-MAILED | — |
| Nov 8, 2024 | C15A | REGISTERED - SEC. 8 (6-YR) ACCEPTED & SEC. 15 ACK. | — |
| Nov 6, 2024 | EROP | TEAS RESPONSE TO OFFICE ACTION-POST REG RECEIVED | — |
| Aug 16, 2024 | PR23 | POST REGISTRATION ACTION MAILED - SEC. 8 & 15 | — |
| Aug 12, 2024 | APRE | CASE ASSIGNED TO POST REGISTRATION PARALEGAL | — |
| Jan 26, 2024 | E815 | TEAS SECTION 8 & 15 RECEIVED | — |
| Mar 20, 2023 | REM1 | COURTESY REMINDER - SEC. 8 (6-YR) E-MAILED | — |
| Sep 4, 2020 | CHAN | APPLICANT/CORRESPONDENCE CHANGES (NON-RESPONSIVE) ENTERED | — |
| Sep 4, 2020 | TCCA | TEAS CHANGE OF CORRESPONDENCE RECEIVED | — |
| Sep 4, 2020 | ECDR | TEAS CHANGE OF DOMESTIC REPRESENTATIVES ADDRESS | — |
| Sep 4, 2020 | ARAA | ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED | This event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action. |
| Sep 4, 2020 | REAP | TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED | — |
| Sep 4, 2020 | COAR | TEAS CHANGE OF OWNER ADDRESS RECEIVED | — |
| May 10, 2019 | TCCA | TEAS CHANGE OF CORRESPONDENCE RECEIVED | — |
| Mar 20, 2018 | R.PR | REGISTERED-PRINCIPAL REGISTER | Your trademark is registered on the Principal Register — the strongest form of federal trademark protection. You may use the ® symbol for the covered goods and services. Maintenance filings (Section 8 and renewals) are required to keep the registration alive. |
| Jan 2, 2018 | NPUB | OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED | — |
| Jan 2, 2018 | PUBO | PUBLISHED FOR OPPOSITION | Your mark was published in the USPTO Official Gazette for a 30-day opposition window. During that period, third parties who believe they would be harmed can file an opposition. If no opposition is filed, prosecution usually continues toward registration or a Notice of Allowance. |
| Dec 13, 2017 | NONP | NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED | — |
| Nov 29, 2017 | CNSA | APPROVED FOR PUB - PRINCIPAL REGISTER | — |
| Nov 28, 2017 | TEME | TEAS/EMAIL CORRESPONDENCE ENTERED | — |
| Nov 28, 2017 | CRFA | CORRESPONDENCE RECEIVED IN LAW OFFICE | — |
| Nov 22, 2017 | ALIE | ASSIGNED TO LIE | — |
| Nov 9, 2017 | ERSI | TEAS RESPONSE TO SUSPENSION INQUIRY RECEIVED | — |
| May 25, 2017 | GNS3 | NOTIFICATION OF LETTER OF SUSPENSION E-MAILED | — |
| May 25, 2017 | GNSL | LETTER OF SUSPENSION E-MAILED | — |
| May 25, 2017 | CNSL | SUSPENSION LETTER WRITTEN | — |
| May 19, 2017 | DOCK | ASSIGNED TO EXAMINER | — |
| Mar 3, 2017 | NWOS | NEW APPLICATION OFFICE SUPPLIED DATA ENTERED | — |
| Feb 28, 2017 | NWAP | NEW APPLICATION ENTERED | — |